Loading…

Clinical pharmacokinetics of nitrates

The pharmacokinetics of organic nitrates are discussed with emphasis on the possible clinical relevance. For glyceryl trinitrate, the measurement of plasma concentrations is very difficult. Its pharmacokinetics are unusual, with a very rapid disappearance from plasma, and large intraindividual and i...

Full description

Saved in:
Bibliographic Details
Published in:Cardiovascular drugs and therapy 1994-10, Vol.8 (5), p.693-699
Main Author: BOGAERT, M. G
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c340t-da3d50861c6f47f371bc568f8b8c69bc325b7aea600af4bf4f21045c691e221b3
cites cdi_FETCH-LOGICAL-c340t-da3d50861c6f47f371bc568f8b8c69bc325b7aea600af4bf4f21045c691e221b3
container_end_page 699
container_issue 5
container_start_page 693
container_title Cardiovascular drugs and therapy
container_volume 8
creator BOGAERT, M. G
description The pharmacokinetics of organic nitrates are discussed with emphasis on the possible clinical relevance. For glyceryl trinitrate, the measurement of plasma concentrations is very difficult. Its pharmacokinetics are unusual, with a very rapid disappearance from plasma, and large intraindividual and interindividual variations. After oral administration, there seems to be a very extensive first-pass hepatic extraction and the plasma concentrations are often below the detection limit; after sublingual administration, glyceryl trinitrate appears in plasma. With transdermal glyceryl trinitrate controlled-release systems, plasma concentrations of glyceryl trinitrate can be maintained over 24 hours, although with fluctuations and important intraindividual and interindividual variability. After administration of glyceryl trinitrate via different routes, glyceryl dinitrates and mononitrates are present in plasma. The pharmacokinetics of isosorbide dinitrate are somewhat easier to understand. The substance disappears less rapidly from the plasma than does glyceryl trinitrate. After oral administration, there is also a hepatic first-pass extraction; the plasma concentrations can be prolonged by administering slow-release products. Sublingual administration leads to higher plasma concentrations than oral administration. Isosorbide dinitrate is metabolized in the organism to isosorbide 5-mononitrate and isosorbide 2-mononitrate, which both have vasodilator activity: after administration of isosorbide dinitrate, the mononitrates, and mainly the 5-mononitrate, reach very high concentrations in plasma. Isosorbide 5-mononitrate has been studied in its own right as an antianginal agent: it is completely absorbed after oral administration; it has a half-life of around 4 hours, and oral standard and controlled-release formulations have been extensively studied.
doi_str_mv 10.1007/bf00877116
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_77765742</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>77765742</sourcerecordid><originalsourceid>FETCH-LOGICAL-c340t-da3d50861c6f47f371bc568f8b8c69bc325b7aea600af4bf4f21045c691e221b3</originalsourceid><addsrcrecordid>eNo9kDtPwzAURi0EKqWwsCNlAAakwPUjvs4IFQWkSiwwR7ZrC0Ne2OnAvyeoodM3nKNvOIScU7ilAHhnPIBCpFQekDktkOfIBD0kcygZ5JyBPCYnKX3CKJelmpEZKuRCyjm5WtahDVbXWf-hY6Nt9xVaNwSbss5nbRiiHlw6JUde18mdTbsg76vHt-Vzvn59elner3PLBQz5RvNNAUpSK71Az5EaW0jllVFWlsZyVhjUTksA7YXxwjMKohgZdYxRwxfkevfbx-5769JQNSFZV9e6dd02VYgoCxRsFG92oo1dStH5qo-h0fGnolD9NakeVv9NRvliet2axm326hRh5JcT12ks4aNubUh7jXMExgX_BWBwZxc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>77765742</pqid></control><display><type>article</type><title>Clinical pharmacokinetics of nitrates</title><source>Springer Nature - Connect here FIRST to enable access</source><creator>BOGAERT, M. G</creator><creatorcontrib>BOGAERT, M. G</creatorcontrib><description>The pharmacokinetics of organic nitrates are discussed with emphasis on the possible clinical relevance. For glyceryl trinitrate, the measurement of plasma concentrations is very difficult. Its pharmacokinetics are unusual, with a very rapid disappearance from plasma, and large intraindividual and interindividual variations. After oral administration, there seems to be a very extensive first-pass hepatic extraction and the plasma concentrations are often below the detection limit; after sublingual administration, glyceryl trinitrate appears in plasma. With transdermal glyceryl trinitrate controlled-release systems, plasma concentrations of glyceryl trinitrate can be maintained over 24 hours, although with fluctuations and important intraindividual and interindividual variability. After administration of glyceryl trinitrate via different routes, glyceryl dinitrates and mononitrates are present in plasma. The pharmacokinetics of isosorbide dinitrate are somewhat easier to understand. The substance disappears less rapidly from the plasma than does glyceryl trinitrate. After oral administration, there is also a hepatic first-pass extraction; the plasma concentrations can be prolonged by administering slow-release products. Sublingual administration leads to higher plasma concentrations than oral administration. Isosorbide dinitrate is metabolized in the organism to isosorbide 5-mononitrate and isosorbide 2-mononitrate, which both have vasodilator activity: after administration of isosorbide dinitrate, the mononitrates, and mainly the 5-mononitrate, reach very high concentrations in plasma. Isosorbide 5-mononitrate has been studied in its own right as an antianginal agent: it is completely absorbed after oral administration; it has a half-life of around 4 hours, and oral standard and controlled-release formulations have been extensively studied.</description><identifier>ISSN: 0920-3206</identifier><identifier>EISSN: 1573-7241</identifier><identifier>DOI: 10.1007/bf00877116</identifier><identifier>PMID: 7873466</identifier><identifier>CODEN: CDTHET</identifier><language>eng</language><publisher>Dordrecht: Springer</publisher><subject>Angina Pectoris - drug therapy ; Antianginal agents. Coronary vasodilator agents ; Biological and medical sciences ; Cardiovascular system ; Delayed-Action Preparations ; Drug Administration Routes ; Half-Life ; Humans ; Isosorbide Dinitrate - administration &amp; dosage ; Isosorbide Dinitrate - analogs &amp; derivatives ; Isosorbide Dinitrate - blood ; Isosorbide Dinitrate - pharmacokinetics ; Isosorbide Dinitrate - therapeutic use ; Liver - metabolism ; Medical sciences ; Nitrates - administration &amp; dosage ; Nitrates - blood ; Nitrates - pharmacokinetics ; Nitrates - therapeutic use ; Nitroglycerin - blood ; Nitroglycerin - pharmacokinetics ; Pharmacology. Drug treatments ; Structure-Activity Relationship ; Vasodilation - drug effects ; Vasodilator Agents - blood ; Vasodilator Agents - pharmacokinetics ; Vasodilator Agents - therapeutic use</subject><ispartof>Cardiovascular drugs and therapy, 1994-10, Vol.8 (5), p.693-699</ispartof><rights>1995 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c340t-da3d50861c6f47f371bc568f8b8c69bc325b7aea600af4bf4f21045c691e221b3</citedby><cites>FETCH-LOGICAL-c340t-da3d50861c6f47f371bc568f8b8c69bc325b7aea600af4bf4f21045c691e221b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=3370234$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7873466$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>BOGAERT, M. G</creatorcontrib><title>Clinical pharmacokinetics of nitrates</title><title>Cardiovascular drugs and therapy</title><addtitle>Cardiovasc Drugs Ther</addtitle><description>The pharmacokinetics of organic nitrates are discussed with emphasis on the possible clinical relevance. For glyceryl trinitrate, the measurement of plasma concentrations is very difficult. Its pharmacokinetics are unusual, with a very rapid disappearance from plasma, and large intraindividual and interindividual variations. After oral administration, there seems to be a very extensive first-pass hepatic extraction and the plasma concentrations are often below the detection limit; after sublingual administration, glyceryl trinitrate appears in plasma. With transdermal glyceryl trinitrate controlled-release systems, plasma concentrations of glyceryl trinitrate can be maintained over 24 hours, although with fluctuations and important intraindividual and interindividual variability. After administration of glyceryl trinitrate via different routes, glyceryl dinitrates and mononitrates are present in plasma. The pharmacokinetics of isosorbide dinitrate are somewhat easier to understand. The substance disappears less rapidly from the plasma than does glyceryl trinitrate. After oral administration, there is also a hepatic first-pass extraction; the plasma concentrations can be prolonged by administering slow-release products. Sublingual administration leads to higher plasma concentrations than oral administration. Isosorbide dinitrate is metabolized in the organism to isosorbide 5-mononitrate and isosorbide 2-mononitrate, which both have vasodilator activity: after administration of isosorbide dinitrate, the mononitrates, and mainly the 5-mononitrate, reach very high concentrations in plasma. Isosorbide 5-mononitrate has been studied in its own right as an antianginal agent: it is completely absorbed after oral administration; it has a half-life of around 4 hours, and oral standard and controlled-release formulations have been extensively studied.</description><subject>Angina Pectoris - drug therapy</subject><subject>Antianginal agents. Coronary vasodilator agents</subject><subject>Biological and medical sciences</subject><subject>Cardiovascular system</subject><subject>Delayed-Action Preparations</subject><subject>Drug Administration Routes</subject><subject>Half-Life</subject><subject>Humans</subject><subject>Isosorbide Dinitrate - administration &amp; dosage</subject><subject>Isosorbide Dinitrate - analogs &amp; derivatives</subject><subject>Isosorbide Dinitrate - blood</subject><subject>Isosorbide Dinitrate - pharmacokinetics</subject><subject>Isosorbide Dinitrate - therapeutic use</subject><subject>Liver - metabolism</subject><subject>Medical sciences</subject><subject>Nitrates - administration &amp; dosage</subject><subject>Nitrates - blood</subject><subject>Nitrates - pharmacokinetics</subject><subject>Nitrates - therapeutic use</subject><subject>Nitroglycerin - blood</subject><subject>Nitroglycerin - pharmacokinetics</subject><subject>Pharmacology. Drug treatments</subject><subject>Structure-Activity Relationship</subject><subject>Vasodilation - drug effects</subject><subject>Vasodilator Agents - blood</subject><subject>Vasodilator Agents - pharmacokinetics</subject><subject>Vasodilator Agents - therapeutic use</subject><issn>0920-3206</issn><issn>1573-7241</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1994</creationdate><recordtype>article</recordtype><recordid>eNo9kDtPwzAURi0EKqWwsCNlAAakwPUjvs4IFQWkSiwwR7ZrC0Ne2OnAvyeoodM3nKNvOIScU7ilAHhnPIBCpFQekDktkOfIBD0kcygZ5JyBPCYnKX3CKJelmpEZKuRCyjm5WtahDVbXWf-hY6Nt9xVaNwSbss5nbRiiHlw6JUde18mdTbsg76vHt-Vzvn59elner3PLBQz5RvNNAUpSK71Az5EaW0jllVFWlsZyVhjUTksA7YXxwjMKohgZdYxRwxfkevfbx-5769JQNSFZV9e6dd02VYgoCxRsFG92oo1dStH5qo-h0fGnolD9NakeVv9NRvliet2axm326hRh5JcT12ks4aNubUh7jXMExgX_BWBwZxc</recordid><startdate>19941001</startdate><enddate>19941001</enddate><creator>BOGAERT, M. G</creator><general>Springer</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19941001</creationdate><title>Clinical pharmacokinetics of nitrates</title><author>BOGAERT, M. G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c340t-da3d50861c6f47f371bc568f8b8c69bc325b7aea600af4bf4f21045c691e221b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1994</creationdate><topic>Angina Pectoris - drug therapy</topic><topic>Antianginal agents. Coronary vasodilator agents</topic><topic>Biological and medical sciences</topic><topic>Cardiovascular system</topic><topic>Delayed-Action Preparations</topic><topic>Drug Administration Routes</topic><topic>Half-Life</topic><topic>Humans</topic><topic>Isosorbide Dinitrate - administration &amp; dosage</topic><topic>Isosorbide Dinitrate - analogs &amp; derivatives</topic><topic>Isosorbide Dinitrate - blood</topic><topic>Isosorbide Dinitrate - pharmacokinetics</topic><topic>Isosorbide Dinitrate - therapeutic use</topic><topic>Liver - metabolism</topic><topic>Medical sciences</topic><topic>Nitrates - administration &amp; dosage</topic><topic>Nitrates - blood</topic><topic>Nitrates - pharmacokinetics</topic><topic>Nitrates - therapeutic use</topic><topic>Nitroglycerin - blood</topic><topic>Nitroglycerin - pharmacokinetics</topic><topic>Pharmacology. Drug treatments</topic><topic>Structure-Activity Relationship</topic><topic>Vasodilation - drug effects</topic><topic>Vasodilator Agents - blood</topic><topic>Vasodilator Agents - pharmacokinetics</topic><topic>Vasodilator Agents - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>BOGAERT, M. G</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cardiovascular drugs and therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>BOGAERT, M. G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical pharmacokinetics of nitrates</atitle><jtitle>Cardiovascular drugs and therapy</jtitle><addtitle>Cardiovasc Drugs Ther</addtitle><date>1994-10-01</date><risdate>1994</risdate><volume>8</volume><issue>5</issue><spage>693</spage><epage>699</epage><pages>693-699</pages><issn>0920-3206</issn><eissn>1573-7241</eissn><coden>CDTHET</coden><abstract>The pharmacokinetics of organic nitrates are discussed with emphasis on the possible clinical relevance. For glyceryl trinitrate, the measurement of plasma concentrations is very difficult. Its pharmacokinetics are unusual, with a very rapid disappearance from plasma, and large intraindividual and interindividual variations. After oral administration, there seems to be a very extensive first-pass hepatic extraction and the plasma concentrations are often below the detection limit; after sublingual administration, glyceryl trinitrate appears in plasma. With transdermal glyceryl trinitrate controlled-release systems, plasma concentrations of glyceryl trinitrate can be maintained over 24 hours, although with fluctuations and important intraindividual and interindividual variability. After administration of glyceryl trinitrate via different routes, glyceryl dinitrates and mononitrates are present in plasma. The pharmacokinetics of isosorbide dinitrate are somewhat easier to understand. The substance disappears less rapidly from the plasma than does glyceryl trinitrate. After oral administration, there is also a hepatic first-pass extraction; the plasma concentrations can be prolonged by administering slow-release products. Sublingual administration leads to higher plasma concentrations than oral administration. Isosorbide dinitrate is metabolized in the organism to isosorbide 5-mononitrate and isosorbide 2-mononitrate, which both have vasodilator activity: after administration of isosorbide dinitrate, the mononitrates, and mainly the 5-mononitrate, reach very high concentrations in plasma. Isosorbide 5-mononitrate has been studied in its own right as an antianginal agent: it is completely absorbed after oral administration; it has a half-life of around 4 hours, and oral standard and controlled-release formulations have been extensively studied.</abstract><cop>Dordrecht</cop><pub>Springer</pub><pmid>7873466</pmid><doi>10.1007/bf00877116</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0920-3206
ispartof Cardiovascular drugs and therapy, 1994-10, Vol.8 (5), p.693-699
issn 0920-3206
1573-7241
language eng
recordid cdi_proquest_miscellaneous_77765742
source Springer Nature - Connect here FIRST to enable access
subjects Angina Pectoris - drug therapy
Antianginal agents. Coronary vasodilator agents
Biological and medical sciences
Cardiovascular system
Delayed-Action Preparations
Drug Administration Routes
Half-Life
Humans
Isosorbide Dinitrate - administration & dosage
Isosorbide Dinitrate - analogs & derivatives
Isosorbide Dinitrate - blood
Isosorbide Dinitrate - pharmacokinetics
Isosorbide Dinitrate - therapeutic use
Liver - metabolism
Medical sciences
Nitrates - administration & dosage
Nitrates - blood
Nitrates - pharmacokinetics
Nitrates - therapeutic use
Nitroglycerin - blood
Nitroglycerin - pharmacokinetics
Pharmacology. Drug treatments
Structure-Activity Relationship
Vasodilation - drug effects
Vasodilator Agents - blood
Vasodilator Agents - pharmacokinetics
Vasodilator Agents - therapeutic use
title Clinical pharmacokinetics of nitrates
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T14%3A59%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20pharmacokinetics%20of%20nitrates&rft.jtitle=Cardiovascular%20drugs%20and%20therapy&rft.au=BOGAERT,%20M.%20G&rft.date=1994-10-01&rft.volume=8&rft.issue=5&rft.spage=693&rft.epage=699&rft.pages=693-699&rft.issn=0920-3206&rft.eissn=1573-7241&rft.coden=CDTHET&rft_id=info:doi/10.1007/bf00877116&rft_dat=%3Cproquest_cross%3E77765742%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c340t-da3d50861c6f47f371bc568f8b8c69bc325b7aea600af4bf4f21045c691e221b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=77765742&rft_id=info:pmid/7873466&rfr_iscdi=true